[Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases].

Abstract

During 1991-94 we treated 51 patients with acute myeloid leukaemias and 3 patients with a myelodysplastic syndrome of refractory anaemia with excess of blasts in transformation. The patients received trimethoprim-sulphamethoxazole (TMP-SMX) 1,920 mg daily as a prophylaxis of Pneumocystis carinii infections and selective decontamination of gastrointestinal tract. The majority of patients received TMP-SMX in their first course of chemotherapy with daunorubicin and cytosine arabinoside. Only one of the 18 patients without TMP-SMX prophylaxis during the first course of chemotherapy developed Pneumocystis carinii pneumonia. That pneumonia was successfully treated by intravenous administration of TMP-SMX 1920 mg four times a day. No other Pneumocystis carinii infection was encountered in all other patients during their clinical follow up or in autopsy material of expired patients. TMP-SMX prophylaxis had to be interrupted in 11 patients due to their suspicious allergic skin reactions, however, TMP-SMX was readministered in all without any skin changes attributable to TMP-SMX during next cycles of chemotherapy. TMP-SMX in a given daily dose of 1,920 mg seems to be a successful prophylaxis of Pneumocystis carinii infections in patients with malignant diseases of hematopoiesis.

• Authors: P Lemez, P Rysková, V Votava, M Suchmová, A Jirásek, I Rubík
• Journal: Vnitrni lekarstvi (Vnitr Lek) Vol. 41 Issue 10 Pg. 688-91 (Oct 1995) ISSN: 0042-773X [Print] Czech Republic
• Vernacular Title: Uspĕsná prevence infekce Pneumocystis carinii pomocí trimetoprim-sulfametoxazolu 1,920 mg dennĕ u nemocných se zhoubnými onemocnĕními krvetvorby.
• PMID: 8578700 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Trimethoprim, Sulfamethoxazole Drug Combination

Topics

• Acute Disease
• Adult
• Anemia, Refractory, with Excess of Blasts (immunology)
• Humans
• Immunocompromised Host
• Leukemia, Myeloid (immunology)
• Male
• Opportunistic Infections (prevention & control)
• Pneumonia, Pneumocystis (prevention & control)
• Trimethoprim, Sulfamethoxazole Drug Combination (administration & dosage)